By inhibiting SGLT2 in the kidneys, SGLT-2i promote glucosuria, lowering blood glucose levels and insulin resistance, which can mitigate NAFLD. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.